Safety and efficacy of combination therapy with pegylated interferon alpha-2a and ribavirin in treating patients with chronic hepatitis C and beta-thalassaemia major: a Greek single-center experience.

Authors :: Paschos P
Vlachaki E
Pasvanti C
Sinakos E
Kalpaka A
Klonizakis P
Perifanis V
Source :: Acta haematologica [Acta Haematol] 2011; Vol. 126 (4), pp. 231-3. Date of Electronic Publication: 2011 Sep 21.
Publication Year :: 2011

Subjects :: Adult
Antiviral Agents administration & dosage
Antiviral Agents chemistry
Antiviral Agents therapeutic use
Chelation Therapy
Drug Therapy, Combination adverse effects
Female
Greece
Hepatitis C, Chronic complications
Homozygote
Humans
Interferon alpha-2
Interferon-alpha administration & dosage
Interferon-alpha chemistry
Interferon-alpha therapeutic use
Iron Chelating Agents therapeutic use
Iron Overload complications
Iron Overload prevention & control
Male
Middle Aged
Recombinant Proteins administration & dosage
Recombinant Proteins adverse effects
Recombinant Proteins chemistry
Recombinant Proteins therapeutic use
Ribavirin administration & dosage
Ribavirin chemistry
Ribavirin therapeutic use
Transfusion Reaction
Treatment Outcome
beta-Thalassemia complications
beta-Thalassemia genetics
beta-Thalassemia therapy
Antiviral Agents adverse effects
Hepatitis C, Chronic drug therapy
Interferon-alpha adverse effects
Polyethylene Glycols chemistry
Ribavirin adverse effects
beta-Thalassemia chemically induced

Full Text Access

Tools